Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Fig. 5

Representative baseline ROR1 immunohistochemistry. Representative ROR1 IHC of breast tissue obtained from patients BROR-01 and BROR-04. Left panel: Negative ROR1 staining in non-neoplastic mammary gland (black star) and in tumor area (red star). Top right panel: ROR1 high expressor with 99% of the cells highly positive (3+ = 5%; 2+ = 67%; 1+ = 27%; 0+ = 1%). Bottom right panel: ROR1 low expressor with 48% of the cells weakly positive (3+ = 0%; 2+ = 0.2%; 1+ = 48%; 0+ = 52%). H&E Hematoxylin and eosin, IHC immunohistochemistry

Back to article page